<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A long-term daily dose of <z:chebi fb="0" ids="24564">hexamethylmelamine</z:chebi> was tested in patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e>, nodular and diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> who had failed conventional treatment </plain></SENT>
<SENT sid="1" pm="."><plain>There were no responses among 20 patients with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, 12 with nodular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and 11 with diffuse well-differentiated lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>However, five of 24 patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (21%) responded and seven of 36 (19%) with diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> other than diffuse well-differentiated lymphocytic <z:hpo ids='HP_0002665'>lymphomas</z:hpo> responded </plain></SENT>
<SENT sid="3" pm="."><plain>This new agent is active in selected histologic types of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>